NCT04628767 2026-03-18
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
National Cancer Institute (NCI)
Phase 2/3 Recruiting
Clinical Trials
120 trialsNCT01712490 2026-02-27
A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
Takeda
Phase 3 Completed
NCT03755804 2026-02-23
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT06960577 2026-02-23
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
AstraZeneca
Phase 3 Recruiting
NCT03407144 2026-02-19
MK-3475-667
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT04685616 2026-02-18
RADAR
University College, London
Phase 3 Recruiting
NCT05137262 2026-02-18
A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03033914 2026-02-17
A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting
NCT03907488 2025-12-04
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02979522 2025-11-10
A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
Takeda
Phase 1/2 Active not recruiting
NCT07013565 2025-10-21
ACCELERATE
New York Medical College
Phase 2 Active not recruiting
NCT04383743 2025-09-18
Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer
University of Washington
Phase 2 Completed
NCT03646123 2025-08-28
Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma
Seagen Inc.
Phase 2 Terminated
NCT03159897 2025-08-08
FIL Study on ABVD DD-DI as Upfront Therapy in HL.
Fondazione Italiana Linfomi - ETS
Phase 3 Completed
NCT05180825 2025-08-08
PLGG - MEKTRIC
University Hospital, Strasbourg, France
Phase 2 Recruiting
NCT00002462 2025-08-05
RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin's Disease
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Active not recruiting
NCT00049595 2025-08-05
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Completed
NCT00379041 2025-08-05
Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Active not recruiting
NCT03331341 2025-08-05
Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma
University of Washington
Phase 1/2 Completed
NCT06377566 2025-04-20
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT02299999 2025-01-15
SAFIR02_Breast
UNICANCER
Phase 2 Active not recruiting
NCT03712202 2024-11-06
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma
City of Hope Medical Center
Phase 2 Active not recruiting
NCT04638790 2024-09-27
HL-Russia-1
State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia
Phase 3 Recruiting
NCT02177695 2024-09-19
COXEN
SWOG Cancer Research Network
Phase 2 Completed
NCT00678327 2024-05-08
Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma
University College, London
Phase 3 Completed
NCT06204614 2024-01-12
Drug Screening Using IMD in Bladder Cancer
Brigham and Women's Hospital
Phase EARLY_PHASE1 Unknown
NCT01088750 2023-12-13
EuroNetLP1
Martin-Luther-Universität Halle-Wittenberg
Phase 4 Completed
NCT02181738 2023-11-28
CheckMate 205
Bristol-Myers Squibb
Phase 2 Completed
NCT00352027 2023-09-22
Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma
St. Jude Children's Research Hospital
Phase 2 Completed
NCT03912818 2023-09-11
Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer
Stanford University
Phase 2 Terminated
NCT02343718 2023-08-04
Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours
Canadian Cancer Trials Group
Phase 1 Completed
NCT02412670 2023-07-10
Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00003389 2023-06-29
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT01390584 2023-06-29
Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT00003027 2023-06-22
Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT00003376 2023-06-22
Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT00003701 2023-06-15
Combination Chemotherapy in Treating Patients With Bladder Cancer
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT01700946 2022-09-28
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
Phase 2 Completed
NCT02292979 2022-08-19
BREACH
The Lymphoma Academic Research Organisation
Phase 2 Completed
NCT00006455 2022-05-31
ALCL 99
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Completed
NCT04781725 2021-11-17
INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer
Ottawa Hospital Research Institute
Phase 2 Unknown
NCT00000626 2021-10-27
Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2 Completed
NCT00992030 2021-08-19
R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma
Fondazione Michelangelo
Phase 3 Terminated
NCT01132807 2021-06-14
Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00002566 2021-02-23
Combination Chemotherapy With Bone Marrow Transplantation in Treating Men With Germ Cell Tumors
UNICANCER
Phase 3 Completed
NCT00030654 2020-10-22
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00505635 2020-09-24
Biochemotherapy With Temozolomide for Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00002715 2020-08-12
Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma
Stanford University
Phase 2 Completed
NCT00498979 2020-07-24
Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers
Case Comprehensive Cancer Center
Phase 1 Completed
NCT00002561 2020-04-14
Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin's Disease
Canadian Cancer Trials Group
Phase 3 Completed